Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

Low dose computed tomography (LDCT) screening, together with the recent advances in
targeted and immunotherapies, have shown to improve non-small cell lung cancer (NSCLC) …

Importance Personalized treatment approaches for patients with oligometastatic colorectal
liver metastases are critically needed. We previously defined 3 biologically distinct …

In patients with completely resected non‐small cell lung cancer (NSCLC), postoperative
adjuvant chemotherapy has been associated with improvement in survival by minimizing the …

Introduction Surgical resection is curative for some patients with early lung squamous cell
carcinoma. Staging and clinical factors do not adequately predict recurrence risk. We sought …

Abstract Objectives The Lepidic Component (LP) identifies a subgroup with an excellent
prognosis for lung adenocarcinoma (LUAD). Our research aimed to propose an improved …

Lung cancer is the primary cause of cancer-related mortality, claiming approximately 1.79
million lives globally in 2020, with an estimated 2.21 million new cases diagnosed within the …

Importance Improved staging for non–small cell lung cancer (NSCLC) represents a critical
unmet need. External validations of the eighth edition of the TNM staging system have …

Objectives This retrospective study aimed to elucidate the effect of epidermal growth factor
receptor (EGFR) gene mutations on the prognosis of patients with pathological stage II–IIIA …

Although surgery for early-stage lung cancer offers the best chance of cure, recurrence still
occurs between 30 and 50% of the time. Why patients frequently recur after complete …